You searched for Pirtobrutinib - Page 3 of 10

ASH 2022: Dr. Jennifer Woyach on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a BTK Inhibitor

March 16, 2023

Pirtobrutinib continues to demonstrate promising and durable efficacy in heavily pre-treated patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), who have been previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who progressed on previous BTK inhibitors.

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor

February 15, 2023

Pirtobrutinib was generally well-tolerated, and most patients did not experience high-grade recurrence of the adverse event that led to discontinuation of the prior covalent Bruton tyrosine kinase inhibitor (BTKi). Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who could not tolerate previous covalent BTKi treatment.

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Richter’s Transformation

February 6, 2023

Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 30, 2023

On 1/27/23 Loxo@Lilly announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

ASH 2021: Dr. Anthony Mato on Updated Results from the BRUIN Study of Non-Covalent BTK Inhibitor Pirtobrutinib

September 13, 2022

We discuss updated results from the BRUIN study, a phase 1/2 clinical trial of pirtobrutinib in patients with advanced B-cell malignancies, including CLL, who have received >2 prior therapies.

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

February 24, 2022

Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).

EHA 2021 Top Pick #5: Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL / SLL: Results From the Phase I/II BRUIN Study

October 4, 2021

Dr. Lindsey Roeker of MSKCC, NYC, NY presented results at 2021 European Hematology Association Virtual Congress, (EHA 2021).

Updated Results of a BTK Degrader for Relapsed CLL

September 16, 2026

BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL.

CLL Society Backs the Next Breakthroughs in CLL / SLL Care with 2026 Research Awards

August 11, 2026

2026 Research Program supports studies aimed at overcoming treatment resistance and improving long-term outcomes for CLL and SLL patients

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Pirtobrutinib – Page 3